Quidel is maker of InflammaDry and QuickVue Adenovirus Tests
Quidel’s Eye Health solutions, InflammaDry and QuickVue, are rapid, lateral-flow based, point-of-care products for the detection of infectious diseases and conditions of the eye. InflammaDry detects elevated levels of MMP-9, a key inflammatory marker for dry eye. QuickVue is a test that differentiates between the viral (adenoviral) and bacterial form of acute conjunctivitis (pink eye). Both products utilize innovative patented technology, are FDA-cleared, CE marked, and CLIA waived.
Quidel Corporation (Nasdaq: QDEL) is a San Diego, California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in California, at our research and manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
Additional Lines: Sofia 2, QuickVue